Propiverine versus Tolterodine: Efficacy and Tolerability in Patients with Overactive Bladder
Author:
Publisher
Elsevier BV
Subject
Urology
Reference10 articles.
1. Economic and social impact of OAB;Kelleher;Eur Urol Suppl,2002
2. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder;Chapple;Expert Opin Invest Drugs,2004
3. Oxybutynin and the overactive bladder;Andersson;World J Urol,2001
4. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic);Madersbacher;World J Urol,2001
5. The emerging role of solifenacin in the treatment of overactive bladder;Robinson;Expert Opin Invest Drugs,2004
Cited by 47 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders;Pharmacological Reviews;2023-03-14
2. Assessment of the continuity of treatment among patients using anticholinergic medication;Annals of Clinical and Analytical Medicine;2023-03-01
3. Correlations of mean voided volume with other parameters of overactive bladder syndrome;Continence;2023-03
4. Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment;Neurourology and Urodynamics;2022-05-20
5. Efficacy and safety of propiverine in patients with overactive bladder and neurogenic detrusor overactivity;Pharmacy & Pharmacology International Journal;2022-04-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3